Intralipid

Soybean oil, the active ingredient in Intralipid, is a lipid emulsion presented as an emulsion for intravenous infusion use. It provides calories and essential fatty acids for patients who require parenteral nutrition and cannot receive enteral feeding, especially in critical care settings.

GNH USA supplies Intralipid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide through regulated supply chains that maintain product integrity and meet local regulatory requirements and provide reliable access to essential nutrition support.

Intralipid is a lipid emulsion used in parenteral nutrition to supply calories and essential fatty acids. - Parenteral nutrition: Provides caloric and fatty‑acid support for patients who cannot be fed enterally. - Essential fatty acid deficiency prevention: Supplies linoleic and alpha‑linolenic acids to avoid deficiency during long‑term PN. - Critical care support: Delivers energy and membrane components for critically ill patients requiring intravenous nutrition.

Intralipid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hypertriglyceridemia: Elevated serum triglyceride levels. - Fever or chills during infusion. - Nausea or vomiting. - Infusion site erythema or pain. - Mild respiratory wheeze. - Transient hypotension.

Serious or Rare Side Effects: - Fat overload syndrome: severe metabolic disturbance. - Anaphylactic or severe allergic reaction. - Pulmonary embolism from lipid droplets. - Thrombocytopenia or coagulopathy. - Hepatic dysfunction or cholestasis. - Severe metabolic acidosis.

Before initiating Intralipid therapy, clinicians should consider several safety measures. - Assess triglyceride levels: Monitor serum triglycerides before and during treatment. - Check for allergies: Avoid in patients with known soy or egg protein hypersensitivity. - Use aseptic technique: Ensure sterile handling to prevent infection. - Limit infusion rate: Follow recommended maximum rates to reduce fat overload risk. - Review lipid‑soluble drug interactions: Adjust concomitant therapies as needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intralipid can affect the pharmacokinetics of several drugs and should be used with caution.

Major Interactions (Avoid): - Propofol: Combined lipid load may cause severe hypertriglyceridemia. - Corticosteroids: May increase serum triglyceride concentrations. - Heparin: Can potentiate lipolysis leading to low triglyceride levels. - Lipid‑soluble medications: May alter distribution and efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: Lipid emulsion may affect INR monitoring. - Phenytoin: Protein binding may be altered, requiring level checks. - Cyclosporine: May increase risk of hyperlipidemia, necessitating lipid monitoring.